Efficacy of retreatment with rituximab in patients with primary Sjögren's syndrome

Clin Exp Rheumatol. 2015 May-Jun;33(3):443-4. Epub 2015 Apr 16.

Authors

Petra M Meiners¹, Suzanne Arends², Jiska M Meijer³, Rada V Moerman², Fred K L Spijkervet¹, Arjan Vissink¹, Hendrika Bootsma²

Affiliations

¹ Department of Oral and Maxillofacial Surgery, University of Groningen, University Medical Center Groningen, The Netherlands.
² Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, The Netherlands.
³ Department of General Practice, University of Groningen, University Medical Center Groningen, The Netherlands.

PMID: 25897541

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Adult
Aged
Antibodies, Monoclonal, Murine-Derived / administration & dosage*
Antibodies, Monoclonal, Murine-Derived / adverse effects
Female
Humans
Immunosuppressive Agents / administration & dosage*
Immunosuppressive Agents / adverse effects
Male
Middle Aged
Randomized Controlled Trials as Topic
Recurrence
Remission Induction
Retreatment
Rituximab
Sjogren's Syndrome / diagnosis
Sjogren's Syndrome / drug therapy*
Time Factors
Treatment Outcome

Substances

Antibodies, Monoclonal, Murine-Derived
Immunosuppressive Agents
Rituximab